ChemicalBook > CAS DataBase List > Radotinib

Radotinib

Radotinib Structure
Radotinib
  • CAS No.926037-48-1
  • Chemical Name:Radotinib
  • CBNumber:CB32667981
  • Molecular Formula:C27H21F3N8O
  • Formula Weight:530.5
  • MOL File:926037-48-1.mol
Radotinib Property
  • Density 1.40±0.1 g/cm3(Predicted)
  • storage temp. Store at -20°C
  • solubility ≥26.55 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
  • form solid
  • pka 12.94±0.70(Predicted)
  • color Light yellow to yellow
  • FDA UNII I284LJY110
  • NCI Drug Dictionary Supect
Safety
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordDanger
  • Hazard statements H302-H315-H318-H334-H317-H341-H361-H370-H335-H413
  • Precautionary statements P201-P202-P260-P264-P270-P272-P273-P280-P284-P301+P312-P302+P352-P304+P341-P305+P351+P338-P310-P308+P313-P321-P330-P362+P364-P333+P313-P342+P311-P363-P405-P501

Radotinib Chemical Properties,Usage,Production

  • Description Radotinib, an inhibitor of Bcr–Abl tyrosine kinase,was approved in January 2012 in Korea as a second-line treatment for chronic myeloid leukemia (CML). Radotinib is a TKI with a similar structure to the second-generation TKI, nilotinib, in which a pyridyl group has been replaced with a pyrazinemoiety. The in vitro activity of radotinib against a variety of tumor cell lines is disclosed in an issued patent. Radotinib was significantly more potent than imatinib in all of the cell lines tested. The synthesis of radotinib via amide coupling is described in the patent literature.
  • Originator Il-Yang (Korea)
  • Uses Radotinib is tyrosine kinase inhibitor. In a biological study, it can induce cytotoxicity in c-KIT-positive malignancies including acute myeloid leukemia and small cell lung cancer in human making it potential target agent for treatment of such malignancies. It is a COVID19-related research product.
  • Indications Radotinib (Supect(R), Il-Yang Pharmaceutical) is a Bcr–Abl inhibitor that was approved in South Korea in 2012 for the treatment of imatinib-resistant CML. Radotinib, which has a terminal 4-(pyridine-2-yl) pyrimidine moiety, was developed based on the previously approved Bcr–Abl inhibitors nilotinib. Radotinib has equivalent efficacy with that of other second-generation Bcr–Abl inhibitors and is well tolerated in chronic-phase CML patients. The lower cost of radotinib compared with other FDA-approved Bcr–Abl inhibitors makes it an attractive alternative for the treatment of CML in developing nations.
  • brand name Supect
  • in vitro radotinib couples to bcr-abl and reduce the phosphorylation of bcr-abl target protein crkl. the pre-clinical studies shows superiority of radotinib to imatinib in both wild-type and mutant bcr-abl1 positive cml cell lines. [1]
  • References 1. kim sh, menon h, jootar s et al. efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to bcr-abl1 tyrosine kinase inhibitors. haematologica. 2014 jul;99(7):1191-6.
Radotinib Preparation Products And Raw materials
Raw materials
Preparation Products
Radotinib Suppliers
Global(119)Suppliers
  • Supplier：
    BOC Sciences
  • Tel：+1-631-485-4226
  • Email：inquiry@bocsci.com
  • Country：United States
  • ProdList：19552
  • Advantage：58
  • Supplier：
    career henan chemical co
  • Tel：+86-0371-86658258<br/>+8613203830695
  • Email：factory@coreychem.com
  • Country：China
  • ProdList：29808
  • Advantage：58
  • Supplier：
    TargetMol Chemicals Inc.
  • Tel：+1-781-999-5354<br/>+1-00000000000
  • Email：marketing@targetmol.com
  • Country：United States
  • ProdList：32159
  • Advantage：58
  • Supplier：
    InvivoChem
  • Tel：+1-708-310-1919<br/>+1-13798911105
  • Email：sales@invivochem.cn
  • Country：United States
  • ProdList：6391
  • Advantage：58
Radotinib Spectrum
926037-48-1, RadotinibRelated Search:
  • Inhibitors
  • 合成有机化合物配体
  • 标准品
  • 细胞生物学试剂
  • 有机光电
  • 抑制剂
  • 小分子抑制剂，天然产物
  • 小分子抑制剂
  • C27H21F3N8O
  • 雷度替尼,10 MM DMSO 溶液
  • RADOTINIB 拉多替尼
  • 雷多替尼
  • 4-甲基-N-(3-(4-甲基-1H-咪唑-1-基)-5-(三氟甲基)苯基)-3-((4-(吡嗪-2-基)嘧啶-2-基)氨基)苯甲酰胺
  • BCR-ABL1抑制剂(RADOTINIB)
  • 拉多替尼
  • 雷度替尼
  • 926037-48-1
  • Radotinib, 10 mM in DMSO
  • Testosterone Impurity 43
  • Supect
  • Radotinib HCl
  • CS-1712
  • IY5511 HCl.
  • RADOTINIB; IY5511 HCL.
  • Benzamide, 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(2-pyrazinyl)-2-pyrimidinyl]amino]-
  • 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phe...
  • 4-Methyl-N-[3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl]-3-(4-(pyrazin-2-yl)pyrimidin-2-ylamino)benzamide
  • Radotinib(IY-5511)
  • Radotinib
  • IY5511

Home

My